- Report
- October 2024
- 193 Pages
Global
From €3389EUR$3,545USD£2,837GBP
€3766EUR$3,939USD£3,152GBP
- Report
- October 2024
- 195 Pages
Global
From €3389EUR$3,545USD£2,837GBP
€3766EUR$3,939USD£3,152GBP
- Report
- October 2024
- 185 Pages
Global
From €3389EUR$3,545USD£2,837GBP
€3766EUR$3,939USD£3,152GBP
- Report
- July 2024
- 100 Pages
Global
From €5689EUR$5,950USD£4,762GBP
- Report
- April 2025
- 354 Pages
Global
From €5354EUR$5,600USD£4,482GBP
- Report
- February 2024
- 126 Pages
Global
From €2859EUR$2,990USD£2,393GBP
- Report
- April 2023
- 110 Pages
Global
From €4541EUR$4,750USD£3,802GBP
- Report
- December 2022
- 118 Pages
Global
From €4302EUR$4,500USD£3,601GBP
- Report
- February 2024
- 90 Pages
Global
From €3500EUR$3,921USD£3,032GBP
- Report
- October 2023
- 93 Pages
Global
From €3500EUR$3,921USD£3,032GBP
- Report
- July 2023
- 90 Pages
Global
From €3500EUR$3,921USD£3,032GBP
- Report
- April 2025
- 50 Pages
Global
From €2534EUR$2,650USD£2,121GBP
- Report
- April 2025
- 50 Pages
Global
From €2534EUR$2,650USD£2,121GBP
- Report
- April 2025
- 50 Pages
Global
From €2534EUR$2,650USD£2,121GBP
- Report
- April 2025
- 50 Pages
Global
From €2534EUR$2,650USD£2,121GBP
- Report
- April 2025
- 50 Pages
Global
From €2534EUR$2,650USD£2,121GBP

Dextran is a polysaccharide used in hematological drugs, primarily as a plasma expander. It is used to treat conditions such as hypovolemia, anemia, and thrombocytopenia. It is also used to reduce the risk of blood transfusions and to reduce the risk of complications from surgery. Dextran is available in a variety of formulations, including intravenous, intramuscular, and oral.
The dextran market is a growing segment of the hematological drugs market. It is used in a variety of medical applications, including the treatment of anemia, thrombocytopenia, and hypovolemia. It is also used to reduce the risk of blood transfusions and to reduce the risk of complications from surgery.
Some of the companies in the dextran market include Baxter International, Fresenius Kabi, B. Braun Melsungen AG, Grifols, and Octapharma. Show Less Read more